Maha Katabi Sells 340,000 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) Director Maha Katabi sold 340,000 shares of the firm’s stock in a transaction on Monday, March 25th. The shares were sold at an average price of $40.50, for a total value of $13,770,000.00. Following the completion of the transaction, the director now owns 2,793,987 shares of the company’s stock, valued at approximately $113,156,473.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Maha Katabi also recently made the following trade(s):

• On Thursday, March 21st, Maha Katabi sold 81,009 shares of Vera Therapeutics stock. The shares were sold at an average price of $44.20, for a total value of $3,580,597.80.
• On Tuesday, January 30th, Maha Katabi acquired 161,290 shares of Vera Therapeutics stock. The shares were bought at an average cost of $31.00 per share, for a total transaction of $4,999,990.00.

Vera Therapeutics Stock Performance

Vera Therapeutics stock opened at $43.83 on Thursday. The stock’s 50-day moving average is $39.76 and its 200-day moving average is $22.93. The company has a market cap of $2.30 billion, a price-to-earnings ratio of -19.14 and a beta of 1.10. The company has a debt-to-equity ratio of 0.20, a current ratio of 6.97 and a quick ratio of 6.97. Vera Therapeutics, Inc. has a 12 month low of $5.95 and a 12 month high of $50.78.

Analyst Ratings Changes

VERA has been the topic of a number of analyst reports. JPMorgan Chase & Co. decreased their price objective on Vera Therapeutics from $25.00 to $22.00 and set an “overweight” rating on the stock in a research note on Thursday, November 30th. Cantor Fitzgerald initiated coverage on Vera Therapeutics in a research note on Monday, January 8th. They issued an “overweight” rating on the stock. Oppenheimer initiated coverage on Vera Therapeutics in a research note on Thursday, January 25th. They issued an “outperform” rating and a $26.00 price target on the stock. Wedbush raised their price target on Vera Therapeutics from $21.00 to $34.00 and gave the stock a “neutral” rating in a research note on Thursday, March 21st. Finally, Raymond James raised Vera Therapeutics from an “outperform” rating to a “strong-buy” rating and raised their price target for the stock from $29.00 to $37.00 in a research note on Friday, January 26th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Vera Therapeutics has a consensus rating of “Buy” and a consensus price target of $32.29.

Hedge Funds Weigh In On Vera Therapeutics

Large investors have recently modified their holdings of the company. Metropolitan Life Insurance Co NY raised its holdings in shares of Vera Therapeutics by 42.2% in the 2nd quarter. Metropolitan Life Insurance Co NY now owns 1,888 shares of the company’s stock worth $30,000 after purchasing an additional 560 shares during the period. Tower Research Capital LLC TRC raised its holdings in shares of Vera Therapeutics by 810.4% during the 1st quarter. Tower Research Capital LLC TRC now owns 4,834 shares of the company’s stock valued at $38,000 after buying an additional 4,303 shares during the period. Ameritas Investment Partners Inc. raised its holdings in shares of Vera Therapeutics by 163.1% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,792 shares of the company’s stock valued at $45,000 after buying an additional 1,731 shares during the period. UBS Group AG purchased a new stake in shares of Vera Therapeutics during the 1st quarter valued at about $47,000. Finally, Royal Bank of Canada raised its holdings in shares of Vera Therapeutics by 94.8% during the 2nd quarter. Royal Bank of Canada now owns 3,339 shares of the company’s stock valued at $54,000 after buying an additional 1,625 shares during the period. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis.